Goldenrod Therapeutics develops a small molecule to prevent pathogenic activity in immune cells.
Goldenrod Therapeutics has raised $6.5M in total funding. The most recent round was Seed. The last funding was announced in June 2026.
Goldenrod Therapeutics's investors include Ataxia Ventures, Fannin Innovation Studio.
Goldenrod Therapeutics is headquartered in Houston, United States.
Goldenrod Therapeutics develops a small molecule to prevent pathogenic activity in immune cells.
Goldenrod Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Goldenrod Therapeutics — Funding & Investors." VCBacked, June 4, 2026, https://www.vcbacked.co/company/goldenrod-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Goldenrod Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/goldenrod-therapeutics
{{cite web |title=Goldenrod Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/goldenrod-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated